Nanobac Pharmaceuticals, Incorporated
NNBP
$0.00
$0.000.00%
OTC PK
| 12/31/2007 | 09/30/2007 | ||||
|---|---|---|---|---|---|
| Revenue | -24.14% | 141.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -24.14% | 141.67% | |||
| Cost of Revenue | -21.28% | 147.37% | |||
| Gross Profit | -36.36% | 120.00% | |||
| SG&A Expenses | 97.24% | -41.61% | |||
| Depreciation & Amortization | -0.70% | -0.61% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.00% | -20.61% | |||
| Operating Income | -23.51% | 21.18% | |||
| Income Before Tax | -39.64% | -16.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -39.64% | -16.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -39.64% | -16.63% | |||
| EBIT | -23.51% | 21.18% | |||
| EBITDA | -30.10% | 25.39% | |||
| EPS Basic | -38.24% | -17.24% | |||
| Normalized Basic EPS | 19.05% | -16.67% | |||
| EPS Diluted | -38.24% | -17.24% | |||
| Normalized Diluted EPS | 19.05% | -16.67% | |||
| Average Basic Shares Outstanding | 1.17% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.17% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||